Brief: Sandoz Completes Strategic Acquisition Of Just-Evotec Biologics EU Sas, Asserting Biosimilars Leadership
Dec 8 (Reuters) - Sandoz Group AG SDZ.S: SANDOZ COMPLETES STRATEGIC ACQUISITION OF JUST-EVOTEC BIOLOGICS EU SAS, ASSERTING BIOSIMILARS LEADERSHIP SANDOZ GROUP AG - STRENGTHENS POSITION TO CAPTURE PROJECTED >USD 300 BILLION BIOSIMILARS LOSS OF EXCLUSIVITY (LOE) MARKET OPPORTUNITY OVER NEXT DECADE SANDOZ GROUP AG - NO IMPACT ON 2025 GUIDANCE FROM ACQUISITION Source text: ID:nEQH0hH1a Further company coverage: SDZ.S (Gdansk Newsroom) (((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600);))
Recent news on Sandoz AG
See all newsPfizer dismissed from US states' drug price-fixing lawsuit (updated)
Pfizer dismissed from US states' drug price-fixing lawsuit
Factbox: Major investment pledges at Choose France summit
Press Digest: Financial Times - June 1
Media: Sandoz warns cheap Chinese imports threaten Europe’s antibiotic supply- FT